^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IL5 (Interleukin 5)

    i
    Other names: IL5, Interleukin 5, IL-5, TRF, Eosinophil Differentiation Factor, T-Cell Replacing Factor, Interleukin-5, EDF, Colony-Stimulating Factor, Eosinophil, B-Cell Differentiation Factor I, Interleukin 5 (Colony-Stimulating Factor, Eosinophil), B Cell Differentiation Factor I
    5d
    A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=318, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P2 trial
    |
    IL5 (Interleukin 5)
    7d
    A short bout of exercise impacts TH2 inflammation of patients with obesity and well-controlled asthma. (PubMed, Ann Thorac Med)
    A short bout of exercise modifies the inflammatory cytokine profile in all participants, with the most significant changes observed in the O-A group. Future studies on exercise training should include inflammatory cytokine measurements to validate these findings and further explore the unique inflammatory responses in obese asthmatic patients.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL13 (Interleukin 13) • IL5 (Interleukin 5) • LEP (Leptin)
    7d
    Cytokines in patients with Posner-Schlossman syndrome. (PubMed, Front Immunol)
    IL-6 may serve as a biomarker reflecting both inflammation and tissue damage in PSS. Note: CECD, corneal endothelial cell density; RECL, relative decrease in CECD loss between the affected eye and the fellow eye.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IFNA1 (Interferon Alpha 1) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
    10d
    IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders. (PubMed, J Hematol Oncol)
    IL-5 CAR-T cell therapy represents a promising targeted therapeutic approach for IL-5Rα+ hypereosinophilic disorders. Its ability to target eosinophils and their precursors across all developmental stages in BM and PB addresses a critical unmet medical need in refractory HES and CEL.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • IL5 (Interleukin 5)
    10d
    INAPRA: Immune Nutrition in Pediatric Respiratory Allergy (clinicaltrials.gov)
    P=N/A, N=40, Completed, Federico II University | Recruiting --> Completed
    Trial completion
    |
    IL13 (Interleukin 13) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
    12d
    Investigating associations between serum inflammatory cytokines at the time of second mild traumatic brain injury with acute neurological signs, axonal injury and behavioural outcomes in male Sprague-Dawley rats. (PubMed, Brain Commun)
    There were no other significant correlations between circulating cytokine levels and post-injury outcomes following correction for multiple comparisons. These findings provide initial, hypothesis-generating evidence that higher levels of circulating inflammatory cytokines at the time of a second mild traumatic brain injury may be associated with decreased susceptibility to a second mild traumatic brain injury, highlighting the complex role of inflammation in repeated mild traumatic brain injury.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL10 (Interleukin 10) • IL13 (Interleukin 13) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
    22d
    Research progress of Type II immune responses in cancer therapy (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
    This "pro-tumor vs. anti-tumor" duality underscores the pivotal yet paradoxical role of Type II immunity in tumor immunoregulation. Here, we systematically review the dual functions of Type II immune responses in tumor immunity and their translational potential for next-generation cancer immunotherapy.
    Review • Journal
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • STAT6 (Signal transducer and activator of transcription 6) • IL4 (Interleukin 4) • IL5 (Interleukin 5) • IL33 (Interleukin 33)
    23d
    Evaluation of the effect of oxycodone on serum inflammatory factor levels in children after congenital heart surgery (ChiCTR2600116700)
    P=N/A, N=800, Not yet recruiting, Shanghai Children's Medical Center; Shanghai Children's Medical Center
    New trial
    |
    IL4 (Interleukin 4) • IL5 (Interleukin 5)
    23d
    Study on the mechanism of inflammatory endotype in odontogenic sinusitis (ChiCTR2600116708)
    P=N/A, N=300, Not yet recruiting, Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University
    New trial
    |
    IL5 (Interleukin 5)
    23d
    Efficacy evaluation and multimodal mechanism study of Magnetic Seizure Therapy in adolescent patients with mental disorders (ChiCTR2500114164)
    P=N/A, N=150, Recruiting, Nanjing Brain Hospital; Nanjing Brain Hospital
    New trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
    24d
    A Phase Ib Study of RC1416 Injection (clinicaltrials.gov)
    P1, N=40, Completed, Nanjing RegeneCore Biotech Co., Ltd. | Recruiting --> Completed | Trial completion date: Jan 2026 --> Sep 2025
    Trial completion • Trial completion date
    |
    IL13 (Interleukin 13) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
    24d
    Observational Safety study of Short-term Use of Colchicine on inhibiting pro-Inflammatory cytokines in Patients with Heart Failure with Preserved Ejection Fraction (ChiCTR2500103522)
    P=N/A, N=100, Completed, The First Hospital of Hebei Medical University; The First Hospital of Hebei Medical University | Not yet recruiting --> Completed
    Trial completion
    |
    IL6 (Interleukin 6) • IL4 (Interleukin 4) • IL5 (Interleukin 5)